Willow Biosciences Inc.
WLLW.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.57M | 3.38M | 2.10M | 1.36M | 706.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.57M | 3.38M | 2.10M | 1.36M | 706.20K |
| Cost of Revenue | 955.30K | 1.00M | 3.63M | 3.78M | 4.32M |
| Gross Profit | 4.96M | 3.72M | -1.53M | -2.42M | -3.61M |
| SG&A Expenses | 2.45M | 2.78M | 3.09M | 2.92M | 3.32M |
| Depreciation & Amortization | 760.20K | 1.01M | 1.03M | 1.21M | 1.28M |
| Other Operating Expenses | 159.60K | -- | -- | -- | -- |
| Total Operating Expenses | 7.02M | 7.48M | 7.74M | 7.91M | 8.92M |
| Operating Income | -2.45M | -4.10M | -5.64M | -6.56M | -8.22M |
| Income Before Tax | -3.00M | -4.53M | -5.43M | -6.30M | -7.88M |
| Income Tax Expenses | 7.00K | 8.50K | 243.00K | 122.00K | -2.00K |
| Earnings from Continuing Operations | -3.01 | -4.54 | -5.68 | -6.43 | -7.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.01M | -4.54M | -5.68M | -6.43M | -7.88M |
| EBIT | -2.45M | -4.10M | -5.64M | -6.56M | -8.22M |
| EBITDA | -1.95M | -3.47M | -5.13M | -6.00M | -7.64M |
| EPS Basic | -0.02 | -0.03 | -0.04 | -0.05 | -0.06 |
| Normalized Basic EPS | -0.01 | -0.02 | -0.03 | -0.03 | -0.04 |
| EPS Diluted | -0.02 | -0.03 | -0.04 | -0.05 | -0.06 |
| Normalized Diluted EPS | -0.01 | -0.02 | -0.03 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 555.57M | 536.16M | 518.12M | 501.23M | 498.15M |
| Average Diluted Shares Outstanding | 555.57M | 536.16M | 518.12M | 501.23M | 498.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |